ZOMETA® Patient Case Study: Multiple Myeloma – The Clinical Question

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

ZOMETA Patient Case Study: Multiple Myeloma

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Multiple Myeloma Patient Case Study – Marie

Marie T.

Aged 62 years
Lives and works on a family farm
Enjoys walking her dogs with her husband

How would you continue to address Marie's bone health?

After 8 months of VAD, Marie's disease is responding well to treatment
Now that Marie is ready to discontinue VAD therapy, she is questioning whether she needs to continue receiving ZOMETA

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.